Asia On The Move: China Startups Go On Hiring Spree
This article was originally published in PharmAsia News
As investment pours into Chinese biologic startups, a talent hunt is on, underscored by two announcements of new senior appointments at CANbridge and Zai Lab. Meanwhile, clinical research organization ICON has appointed new leadership for Asia and Meiji Seika is strengthening its CNS business.
You may also be interested in...
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Important changes are coming to China's Drug Administration Law as the government aims to address through several revisions a number of key issues since the law’s original enactment in 2019.